High-energy focused extracorporeal shock wave therapy for bone marrow edema syndrome of the hip: A retrospective study. Issue 16 (April 2020)

• Record Type: Journal Article
• Authors: Zhang, Leilei; Cui, Yuzhi; Liang, Dawei; Guan, Jie; Liu, Youwen; Chen, Xiantao
• Other Names: Tu. Wen-Jun section editor.
• Is Part Of: Medicine. Volume 99:Issue 16(2020)
• Publication Date: 2020-04
• Subjects: bone marrow edema syndrome -- extracorporeal shock wave therapy -- hip; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000019747
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The objective of this retrospective study was to evaluate the efficacy of high-energy focused extracorporeal shock wave therapy (HF-ESWT) on painful bone marrow edema syndrome (BMES) of the hip and shorten the natural course of disease. Thirty-four consecutive patients with BMES of the hip were treated with HF-ESWT in our department between August 2017and July 2018. The progression and treatment results of BMES were evaluated by imaging examination and clinical outcomes. The clinical outcomes include hip pain and function which were measured using the visual analog scale (VAS) and Harris hip score (HHS), respectively, and the VAS and HHS of all patients were calculated and evaluated before treatment (s0), at 1 month (s1), 3 months (s2), 6 months (s3)post-treatment. Imaging examination including Pelvic radiographs and frog views and double hip magnetic resonance imaging (MRI) were also obtained and scheduled before treatment, at 1, 3, 6, and the final follow-up post-treatment to exclude avascular necrosis and other pathology. All patients successfully completed the treatment and follow-up. Compared with pretherapy, the pain was alleviated to varying degrees and the HHS was significantly improved, and the VAS was significantly reduced at S1–2 (1- and 3-months post-treatment) after therapeutic intervention ( P < .05). The mean improvements were strongly statistically significant between S0 and S1 and between S1 andS2 ( P < .0001) and less significant between S2 and S3 ( P < .01). The mean improvement between 6 months (S3) and final follow-up (more than 12 months) was not statistically significant. The MRI findings demonstrated that the diffuse BMES in the femoral head and neck disappeared completely. HF-ESWT is a safe, effective, reliable, and noninvasive treatment in patients with painful BMES of the hip, and it can accelerate the recovery of BMES of the hip, shorten the treatment time and course of disease, improve hip joint function and the quality of life of patients.